剂量减少与延迟对卵巢癌患者无进展生存期的影响:OPAL前瞻性队列研究
该研究基于澳大利亚全国前瞻性OPAL队列,纳入634例新诊断上皮性卵巢癌患者,比较三周疗CP与剂量密集DD-CP方案。DD-CP组剂量减少和延迟更常见、完成率更低,但调整年龄、组织学和FIGO分期后两组PFS无差异,且剂量减少或延迟与否PFS相似。
要点
- DD-CP方案因血液学毒性导致更多剂量减少和延迟,完成率显著低于CP。
- 调整混杂因素后,CP与DD-CP两组中位PFS无显著差异。
- 无论是否发生剂量减少或延迟,患者中位PFS相似。
核心结论
- DD-CP方案因血液学毒性需要更多剂量减少和延迟、完成率更低,但CP与DD-CP中位PFS无显著差异。
- 发生剂量减少或延迟的患者与未发生者中位PFS相似。
研究设计与样本
- 澳大利亚全国前瞻性OPAL队列研究,纳入634例可评估的新诊断上皮性卵巢(或腹膜、输卵管)癌患者。
- 309例接受三周疗CP(卡铂AUC 5或6+紫杉醇175 mg/m2),325例接受DD-CP(卡铂AUC 5或6+每周紫杉醇80 mg/m2)。
- 主要终点为PFS。
主要发现
- CP组与DD-CP组完成全部计划化疗剂量的比例分别为66%与40%(p < 0.001)。
- 至少一次治疗延迟的比例分别为28%与58%(p < 0.001),需要至少15%剂量减少的比例分别为29%与49%(p < 0.001)。
- CP组与DD-CP组中位PFS分别为29.2个月[22.9, 43.8]与21.5个月[19.4, 23.1]。
- 调整年龄、组织学和FIGO分期后,两组PFS无差异。
- 无论是否剂量减少或延迟,患者中位PFS相似。
临床怎么用
- 真实世界中DD-CP方案因血液学毒性导致更多剂量调整和延迟,临床需加强毒性管理。
- 剂量减少或延迟未显著影响PFS,支持在毒性发生时进行个体化剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women with ovarian cancer receiving first line chemotherapy in a real world prospective cohort study. METHODS: Patients with newly diagnosed epithelial ovarian (or peritoneal, fallopian tube) cancer enrolled in a national Australian prospective study, OPAL, who commenced three-weekly carboplatin (AUC 5 or 6) and paclitaxel 175 mg/m2 (CP) or carboplatin (AUC 5 or 6) and dose-dense weekly paclitaxel 80 mg/m2 (DD-CP) were eligible. Primary endpoint was PFS. RESULTS: 634 evaluable patients, 309 commenced CP and 325 DD-CP. Patient's age was similar in the two groups (median 62 years, range 21-79). All planned chemotherapy doses were completed by 66% vs 40% (p < 0.001) in the CP and DD-CP groups respectively. There was at least one treatment delay in 28% vs 58% (p < 0.001) in the CP and DD-CP groups, respectively, and 29% vs 49% (p < 0.001), respectively, required at least a 15% dose reduction for either carboplatin or paclitaxel. Median PFS was 29.2 [22.9, 43.8] and 21.5 [19.4, 23.1] months in the CP and DD-CP groups respectively. Adjusting for age, histology and FIGO stage PFS did not differ between treatment groups. Median PFS was similar in patients irrespective of dose reduction or dose delay. CONCLUSION: Patients receiving DD-CP required more dose reductions and delays due to haematological toxicities and lower completion rates than CP without significant difference in median PFS between CP and DD-CP. Median PFS was similar in patients irrespective of dose reduction or dose delay.
引用
- Sivakumaran T, Mileshkin L, Grant P, et al. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecol Oncol. 2020. PMID: 32381362. doi:10.1016/j.ygyno.2020.04.706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。